证券研究报告 医药生物 | 生物制品 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 30 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 李强 SAC：S1350524040001 liqiang01@huayuanstock.com 市场表现： | 基本数据 | | | 2025 | 年 | 04 | 月 | 29 | 日 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | 22.04 | | | | 一 年 内 高 / 低 | 最 | 最 | | | | | | | 30.48/19.46 | | （元） | | | | | | | | | | | 总市值（百万元） | | | | | | | 16,112.89 | | | | 流通市值（百万元） | | | | | | | 15,933.44 | | | | 总股本（百万股） | | | | | | | 731.07 | | | | 资产 ...

Core Viewpoint - The company maintains a positive outlook on its operational performance and future growth despite challenges in stock price and market conditions [1][2][3]. Financial Performance - In 2024, the company achieved a revenue of 81.76 billion yuan, representing a year-on-year increase of 2.67% [31]. - The net profit attributable to shareholders was 21.93 billion yuan, up 23.25% year-on-year [31]. - The net profit excluding non-recurring gains was 20.60 billion yuan, reflecting a 13.47% increase compared to the previous year [31]. Operational Insights - The company reported a significant decrease in operating cash flow, primarily due to changes in customer payment terms and increased cash outflows for imported goods [1]. - The increase in accounts receivable indicates a potential relaxation of credit policies to boost sales [1]. - Inventory levels rose due to slower sales of human albumin and increased reserves of imported albumin [1]. Market Position and Strategy - The company is recognized as a leading player in the blood products industry, with a focus on enhancing its return on equity (ROE) through improved asset efficiency and profitability [1][2]. - The company holds a 44% share of its revenue from imported human albumin, with significant imports from the US, Spain, and Ireland [2]. - The company is actively pursuing a dual strategy of "expanding plasma sources" and "reducing plasma processing" to enhance its market position [11][27]. Industry Trends - The blood products market is expected to maintain a stable demand, influenced by supply-demand dynamics and healthcare policies [20][24]. - The company is closely monitoring the impact of trade tariffs on its imported products, although the exact effects remain uncertain [3][23]. Future Outlook - The company is committed to ongoing innovation and development in the biopharmaceutical sector, with a focus on clinical research and product diversification [11][27]. - The management expresses confidence in the company's ability to navigate market challenges and enhance shareholder value through strategic initiatives [12][31].

Group 1: Company Performance - In Q1 2025, the company reported a revenue of 2.006 billion, a decrease of 2.45% year-on-year, and a net profit of 566 million, down 25.20% year-on-year [5] - The company’s revenue in 2024 was 8.176 billion, with a year-on-year growth of 2.67%, and a net profit of 2.193 billion, an increase of 23.25% [17] - The company’s inventory as of March 31, 2025, was 4.12 billion, primarily consisting of raw materials and finished goods [4] Group 2: Market Dynamics - The blood product industry is experiencing stable demand, with human albumin in a balanced state and immunoglobulin in a tight balance [2] - The pricing of blood products is influenced by supply-demand relationships and healthcare policies, with expectations of continued rigid demand in the future [3][11] Group 3: Research and Development - The company is focusing on key R&D projects, including SR604, which is currently in Phase II clinical trials [4] - The company has initiated R&D on products like protein C and activated prothrombin complex, which have not yet entered clinical trials [2] Group 4: Strategic Initiatives - The company is pursuing a dual strategy of "expanding plasma collection" and "innovative drug development" to enhance its market position [21] - The company plans to utilize a share buyback program, with a total budget of 250 million to 500 million RMB, to boost investor confidence [23] Group 5: Financial Management - The company has implemented measures to enhance shareholder returns, including stock buybacks and cash dividends [24] - The company’s financial leverage and asset efficiency will be optimized to improve its return on equity (ROE) [26]

Core Viewpoint - The blood products industry, once considered a "golden track," is facing significant challenges in Q1 2025, with major companies experiencing over 20% declines in net profits, contrasting sharply with their strong performance in 2024. This downturn is attributed to a combination of price wars, inventory buildup, and technological substitution [1]. Group 1: Financial Performance - TianTan Bio reported a revenue increase of 7.84% to 1.318 billion yuan, but its net profit plummeted by 22.9%. Operating cash flow fell by 65.75%, and accounts receivable surged by 1093%, indicating deteriorating sales collection efficiency [2]. - Boya Bio's revenue grew by 19.49%, yet its net profit decreased by 8.25%, with core products like human albumin seeing price declines of 2.65% to 12% [2]. - Pailin Bio experienced a revenue drop of 14% and a net profit decline of 26.95%, with operating expenses rising to 18.04%, indicating a failure in cost control [2]. - Shanghai Laishi's net profit growth rate fell from 23.25% to -25.20%, highlighting operational pressures despite expansion efforts [2]. Group 2: Industry Dynamics - The industry's sudden performance decline is driven by price wars, inventory accumulation, and technological substitution. In 2024, blood product inventory growth (36.02%) significantly outpaced cost growth (7.12%), forcing companies to lower prices to clear stock. The terminal price of human albumin has dropped to 350-380 yuan per bottle [3]. - Although not included in national procurement, regional alliance negotiations and competition from imported products create "invisible procurement pressure," with imported albumin's market share rising to 69% and over 70% in tertiary hospitals [3]. - Disruptive technologies are eroding the industry's competitive advantages, with plant-based recombinant albumin potentially reducing costs to below 10 yuan per gram, halving current blood-derived product prices. Additionally, recombinant coagulation factor VIII has captured a 30 billion yuan market share, further compressing the premium space for blood-derived products [3]. Group 3: Opportunities and Challenges - The reliance on imports and the threat from recombinant technologies make domestic production crucial for overcoming current challenges. Tariffs on imports from the U.S. could increase imported albumin prices by 10%-15%, highlighting the cost-effectiveness of domestic products, which currently hold a 31% market share that needs to rise above 50% [4]. - Leading companies are accelerating technological advancements, with TianTan Bio achieving a revenue of over 6 million yuan per ton of plasma and aiming for a 50% domestic production rate for coagulation factors. Shanghai Laishi is investing 4.2 billion yuan to acquire Nanyue Bio, increasing its plasma collection stations to over 50, with the top five companies controlling over 80% of plasma collection [4]. - However, the disruptive threat from recombinant technologies remains, with the clinical adaptation and market education for recombinant albumin expected to take 5-8 years, providing traditional companies with a valuable window for transformation [4]. Group 4: Conclusion - The blood products industry's challenges are not coincidental but rather a painful transition in market logic. As price wars and inventory pressures push companies towards efficiency competition, the race for survival in this trillion-yuan market will test not only the number of plasma collection stations but also product quality, cost control, and strategic foresight [5].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has experienced a short-term decline in performance due to temporary production stoppages, but it is expected to benefit from capacity expansion and sustained high growth in plasma collection [4][5] - In 2024, the company achieved a revenue of 2.655 billion yuan, representing a 14% increase year-on-year, and a net profit of 745 million yuan, which is a 21.76% increase [4] - The company’s plasma collection volume exceeded 1,400 tons in 2024, with an expected growth rate of over 15% [6] - The company has signed exclusive licensing and supply agreements to enhance its market presence both domestically and internationally [6] - The company’s gross margin for 2024 was 49.13%, with a net margin of 28.07%, indicating effective cost management and profitability [7] Financial Summary - The company’s projected revenues for 2025, 2026, and 2027 are 3.112 billion yuan, 3.702 billion yuan, and 4.214 billion yuan respectively, with corresponding net profits of 894 million yuan, 1.095 billion yuan, and 1.231 billion yuan [8][11] - The expected growth rates for revenue from 2024 to 2027 are 14%, 17.24%, 18.93%, and 13.83% respectively [11] - The company’s earnings per share (EPS) are projected to increase from 1.02 yuan in 2024 to 1.68 yuan in 2027 [11]

Core Viewpoint - The blood products industry is experiencing a significant divergence in performance among companies, with some reporting growth while others face declines in revenue and profit [1][2]. Group 1: Company Performance in 2024 - Shanghai Laisai (002252) and Tiantan Biological (600161) reported revenue growth of 2.67% and 16.44% respectively, with net profits increasing by 23.25% and 39.58% [1]. - Hualan Biological (002007), Boya Biological (300294), and Bohui Innovation (300318) experienced revenue declines of 18.02%, 34.58%, and 18.53% respectively, while Hualan's net profit fell by 26.57% [1]. - Bohui Innovation managed to turn a profit with a net profit of 0.09 billion yuan, compared to a loss in the previous year [1]. Group 2: Q1 2025 Performance - In Q1 2025, Tiantan Biological, Hualan Biological, and Boya Biological continued to show revenue growth, while Shanghai Laisai, Tiantan Biological, and Paillin Biological saw revenue declines of 2.45%, 0.57%, and 14% respectively [1]. - Hualan Biological's net profit increased by 19.62%, while Shanghai Laisai and Tiantan Biological reported net profit declines of 25.2% and 22.9% respectively [1]. - The decline in profits for Tiantan Biological was attributed to a decrease in product prices that outweighed the benefits of increased sales volume [1]. Group 3: Market Dynamics - The blood products market is expected to maintain stable growth in 2024, with significant competition in the human albumin market due to increased imports [2][3]. - The cancellation of certain medical insurance restrictions is expected to release market demand for coagulation factor products, contributing to their growth [2]. - The overall price trend for blood products is declining, influenced by increased competition and supply exceeding demand for certain products [3]. Group 4: Industry Consolidation - The blood products industry is characterized by high entry barriers, with fewer than 30 companies currently operating due to strict regulations on blood product production [6][7]. - Recent mergers and acquisitions are expected to enhance industry concentration, with leading companies gaining competitive advantages through resource acquisition [6][7]. - Companies like Tiantan Biological and Shanghai Laisai have made significant acquisitions to expand their production capabilities and market presence [7]. Group 5: Market Size and Growth Projections - The blood products market in China reached a scale of 600 billion yuan in 2024, with projections to grow to 780 billion yuan by 2027, reflecting a compound annual growth rate of 11.6% from 2022 to 2027 [8].

Group 1: Company Performance - In Q1, Hualan Biological achieved revenue of 868 million yuan, a year-on-year increase of 10.2% [1] - The net profit attributable to shareholders was 313 million yuan, up 19.62% year-on-year, while the net profit excluding non-recurring gains and losses was 300 million yuan, increasing by 35.35% [1] - The blood products segment generated revenue of 843 million yuan, with a year-on-year growth of 11.98% and a net profit of 291 million yuan, reflecting a 23.47% increase [1] Group 2: Vaccine Business - Hualan Vaccine reported Q1 revenue of 24.28 million yuan, a decline of 29.05% year-on-year, with a net profit of 32.78 million yuan, down 15.06% [2] - The net profit excluding non-recurring gains and losses was 15.42 million yuan, showing an increase of 8.89% [2] - The company anticipates that vaccine sales will improve in Q2 as product approvals and sales efforts ramp up [2] Group 3: Industry Trends - The plasma collection volume for Hualan Biological reached a record high of 1586.37 tons in 2024, marking an 18.18% increase [3] - The blood products industry is experiencing increased merger and acquisition activities, with plasma stations becoming a strategic focus for companies [3] - Notable acquisitions include Boya Biological's purchase of 100% of Green Cross China for 1.82 billion yuan, adding 4 plasma stations, and Tian Tan Biological's acquisition of 5 plasma stations from CSL Asia Pacific [3]

Industry Outlook - The blood products industry in China is expected to maintain high growth due to factors such as improved consumption structure, enhanced plasma utilization, normalized exports, and increased government support [1] - The market capacity for blood products is projected to exceed 100 billion RMB in the future [2] Company Performance - In 2024, the company reported a revenue of 2.655 billion RMB, a year-on-year increase of 14%, and a net profit of 745 million RMB, up 21.76% [4] - The net profit margin for 2024 was 28.07%, reflecting a year-on-year increase of 1.81 percentage points [5] Production and Capacity - The company’s plasma collection volume in 2024 exceeded 1,100 tons, with an expected increase to over 1,400 tons in 2025, representing a growth of over 20% [5][6] - Post-expansion, the annual production capacity is anticipated to exceed 3,000 tons [6][8] Growth Strategies - The company plans to increase the number of plasma collection stations through both organic growth and acquisitions [3] - Continuous R&D efforts will be made to enhance product variety and improve profit margins per ton of plasma [3] Market Position - The overall performance of the blood products industry is strong, with the company positioned favorably compared to peers [4] - The company has received over 10 county-level and 5 city-level approvals for new plasma stations, aiming for significant expansion in 2025 [7] Future Projections - The company aims to maintain double-digit profit growth in 2025 [6] - The fourth-generation intravenous immunoglobulin is expected to be approved in the first half of 2027 [8] Shareholder Engagement - The company has implemented a value management system and is actively pursuing share buyback plans, maintaining a high dividend payout ratio [10]

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price adjusted to RMB 32.50 [1][9]. Core Insights - The company has cleared goodwill impairment risks and is expanding its plasma collection stations through both organic growth and acquisitions, establishing a foundation for future growth. The potential impact of tariffs on imported albumin may benefit domestic albumin products [1][9]. - The company reported a full-year revenue of RMB 1.74 billion in 2024, a decrease of 34.58%, while net profit increased by 67.18% to RMB 397 million, primarily due to a low base from goodwill impairment in 2023 [1][9]. - The product structure is continuously optimized, with blood product revenue growing by 4.32% to RMB 1.51 billion in 2024, despite a slight decline in gross profit margin [1][9]. Financial Summary - Revenue and profit forecasts for the upcoming years have been adjusted, with 2025 EPS projected at RMB 1.16 and 2026 EPS at RMB 1.33, while a new forecast for 2027 EPS is set at RMB 1.50 [1][9]. - The company is expected to maintain a steady growth trajectory, with plasma collection volume projected to reach 630.6 tons in 2024, reflecting a 10.4% increase [1][9]. - The financial outlook includes a projected net profit of RMB 585 million for 2025, with a net profit margin expected to improve over the years [1][9].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 24.42 CNY, compared to the current stock price of 21.64 CNY [4]. Core Views - The company achieved a revenue of 2.655 billion CNY in 2024, representing a year-on-year growth of 14.00%. The net profit attributable to shareholders was 745 million CNY, up 21.76% year-on-year [1]. - In Q4 2024, the company reported a revenue of 764 million CNY, a decline of 19.86% year-on-year, and a net profit of 203 million CNY, down 29.14% year-on-year [1]. - The company is expanding its production capacity, with the annual capacity of the Picefiko project increasing to 1,600 tons and the Guangdong Shuanglin project expected to reach 1,500 tons by mid-2025, ensuring long-term sustainable development [2][3]. Summary by Sections Financial Performance - In 2024, the company achieved a net profit margin of 28.07%, an increase of 1.81 percentage points year-on-year, and a period expense ratio of 16.70%, a decrease of 4.26 percentage points year-on-year [1]. - For Q1 2025, the company reported a revenue of 375 million CNY, a decrease of 14.00% year-on-year, and a net profit of 89 million CNY, down 26.95% year-on-year [2]. Plasma Collection and Expansion - The company adopted a dual strategy of internal growth and external expansion in plasma collection, achieving over 1,400 tons of plasma collection in 2024, which supports product supply and rapid growth in annual operating performance [3]. - The company has completed the acceptance of new plasma stations and is expanding the number of plasma donors to increase collection rates [3]. Product Development - The company has over 10 products in advanced stages of research and development, with significant progress in clinical trials for several key products, enhancing market competitiveness [4]. - The comprehensive utilization rate of plasma is expected to continue increasing with the launch of new products [9]. Future Projections - Revenue growth is projected at 16.2%, 13.9%, and 12.2% for 2025 to 2027, respectively, with net profit growth of 19.8%, 16.5%, and 14.2% during the same period [9].